VEGF bispecifics. | Merck and BioNTech are buying Chinese biotechs to gain PD-(L)1/VEGF bispecifics. AstraZeneca's CEO argued ...
German drugmaker BioNTech has agreed to acquire Chinese biotech company Biotheus to support its oncology strategy and gain ...
Investor's Business Daily on MSN18h
BioNTech Stock Got A IBD RS Rating LiftHow Much Money To Invest Now. Is BioNTech Stock A Buy? BioNTech stock is building a consolidation with a 131.49 buy point.
Shares of vaccine makers fell as President-elect Donald Trump nominated Robert F. Kennedy Jr., a prominent vaccine skeptic, ...
BioNTech is upping its bet on a PD-L1xVEGF-A bispecific, paying $800 million upfront to buy its Chinese partner Biotheus ...
BioNTech said that it is acquiring the Chinese drugmaker Biotheus for $800 million to bolster its cancer strategy. The two ...
BioNTech SE and Biotheus (Biotheus) announced the signing of a definitive agreement for the acquisition of Biotheus, a clinical-stage biotechnology company dedicated to the discovery and development ...
Analysts have set 12-month price targets for BioNTech, revealing an average target of $132.24, a high estimate of $171.00, ...
On Wednesday, BioNTech SE (NASDAQ:BNTX) agreed to acquire Biotheus, a clinical-stage biotechnology company focused on ...
Biotheus’ antibody drug targets PD-L1 and VEGF, a design that’s high on drugmakers’ radars after the success of Summit ...
The Goldman Sachs Group upgraded shares of BioNTech (NASDAQ:BNTX – Free Report) from a neutral rating to a buy rating in a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback